Back To Menu
  • Full Offering
  • Messaging & Branding
  • Media
  • Thought Leadership
  • Patient Engagement
  • Biomedical illustration
  • Social Media
  • Talent Branding
  • Video
  • Team Ten Bridge
  • Join Us
  • Professional development
  • Contact Us

Biotech’s Communications Partner

We guide biotechs through all stages of growth
We guide biotechs through all stages of growth
Our Full Offering
Messaging + Branding
Media
Social Media
Patient Engagement
Video
Team Ten Bridge
Join Us

Follow us on Twitter

@tenbridge
  • Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer
    Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer
  • OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
    ModeX Therapeutics
    OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
  • Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002
    Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002
  • Volastra Therapeutics Named One Of Fierce Biotech’s “Fierce 15” Companies Of 2022
    Volastra Therapeutics Named One Of Fierce Biotech’s “Fierce 15” Companies Of 2022
  • Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration
    Cajal Neuroscience
    Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration
  • Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic
    Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic
  • Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO
    Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO
  • Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology
    Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology
  • Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines
    Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines
  • SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
    SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
  • Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb
    Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb
  • Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology
    Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology
  • Connect With Us
  • One Beacon Street, Suite 08200, Boston MA 02108202-796-3077
2023 © Ten Bridge Communications